Incident haemodialysis and outcomes in the Top End of Australia.


Journal

Australian health review : a publication of the Australian Hospital Association
ISSN: 1449-8944
Titre abrégé: Aust Health Rev
Pays: Australia
ID NLM: 8214381

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 02 11 2018
accepted: 06 01 2019
pubmed: 19 4 2019
medline: 30 1 2021
entrez: 19 4 2019
Statut: ppublish

Résumé

Objective The Northern Territory has the highest incidence of haemodialysis care for end-stage kidney disease in Australia. Although acute kidney injury (AKI) is a recognised risk for chronic kidney disease (CKD), the effect of AKI causing incident haemodialysis (iHD) is unknown. Audits identifying antecedents of iHD may inform health service planning. Thus, the aims of this study were to describe: (1) the development of an iHD recording system involving patients with AKI and CKD; and (2) the incidence, patient characteristics and mortality for patients with dialysis-requiring AKI. Methods A retrospective data linkage study was conducted using eight clinical and administrative datasets of adults receiving iHD during the period from July 2011 to December 2012 within a major northern Australian hospital for AKI without CKD (AKI), AKI in people with pre-existing CKD (AKI/CKD) and CKD (without AKI). The time to death was identified by the Northern Territory Register of deaths. Results In all, 121 iHD treatments were provided for the cohort, whose mean age was 51.5 years with 53.7% female, 68.6% Aboriginal ethnicity and 46.3% with diabetes. iHD was provided for AKI (23.1%), AKI/CKD (47.1%) and CKD (29.8%). The 90-day mortality rate was 25.6% (AKI 39.3%, AKI/CKD 22.8%, CKD 19.4%). The 3-year mortality rate was 45.5% (AKI 53.6%, AKI/CKD 22.8%, CKD 19.4%). The time between requesting data from custodians and receipt of data ranged from 15 to 1046 days. Conclusion AKI in people with pre-existing CKD was a common cause of iHD. Health service planning and community health may benefit from AKI prevention strategies and the implementation of sustainable and permanent linkages with the datasets used to monitor prospective incident haemodialysis. What is known about the topic? AKI is a risk factor for CKD. The Northern Territory has the highest national incidence rates of dialysis-dependent end-stage kidney disease, but has no audit tool describing outcomes of dialysis-requiring AKI. What does this paper add? We audited all iHD and showed 25.6% mortality within the first 90 days of iHD and 45.5% overall mortality at 3 years. AKI in people with pre-existing CKD caused 47.1% of iHD. What are the implications for practitioners? Health service planning and community health may benefit from AKI prevention strategies and the implementation of sustainable and permanent linkages with the datasets used to monitor prospective incident haemodialysis.

Identifiants

pubmed: 30995950
pii: AH18230
doi: 10.1071/AH18230
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Pagination

234-240

Auteurs

Jaquelyne T Hughes (JT)

Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia. Email: william.majoni@nt.gov.au; federica.barzi@nt.gov.au; Tegan.Harris@menzies.edu.au; Lewis.Campbell@nt.gov.au; alan.cass@menzies.edu.au; and Department of Nephrology, Division of Medicine, Royal Darwin Hospital, PO Box 41326, Casuarina, NT 0811, Australia. Email: Selina.Signal@nt.gov.au; Gwendoline.Lowah@nt.gov.au; Jola.Kapojos@sa.gov.au; Asanga.Abeyaratne@nt.gov.au; Madhivanan.Sundaram@nt.gov.au; and Corresponding author. Email: Jaqui.hughes@menzies.edu.au.

Sandawana W Majoni (SW)

Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia. Email: william.majoni@nt.gov.au; federica.barzi@nt.gov.au; Tegan.Harris@menzies.edu.au; Lewis.Campbell@nt.gov.au; alan.cass@menzies.edu.au; and Department of Nephrology, Division of Medicine, Royal Darwin Hospital, PO Box 41326, Casuarina, NT 0811, Australia. Email: Selina.Signal@nt.gov.au; Gwendoline.Lowah@nt.gov.au; Jola.Kapojos@sa.gov.au; Asanga.Abeyaratne@nt.gov.au; Madhivanan.Sundaram@nt.gov.au; and Northern Territory Clinical School, Flinders University, Darwin, NT 0811, Australia. Email: Dianne.Stephens@nt.gov.au.

Federica Barzi (F)

Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia. Email: william.majoni@nt.gov.au; federica.barzi@nt.gov.au; Tegan.Harris@menzies.edu.au; Lewis.Campbell@nt.gov.au; alan.cass@menzies.edu.au.

Tegan M Harris (TM)

Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia. Email: william.majoni@nt.gov.au; federica.barzi@nt.gov.au; Tegan.Harris@menzies.edu.au; Lewis.Campbell@nt.gov.au; alan.cass@menzies.edu.au.

Selina Signal (S)

Department of Nephrology, Division of Medicine, Royal Darwin Hospital, PO Box 41326, Casuarina, NT 0811, Australia. Email: Selina.Signal@nt.gov.au; Gwendoline.Lowah@nt.gov.au; Jola.Kapojos@sa.gov.au; Asanga.Abeyaratne@nt.gov.au; Madhivanan.Sundaram@nt.gov.au.

Gwendoline Lowah (G)

Department of Nephrology, Division of Medicine, Royal Darwin Hospital, PO Box 41326, Casuarina, NT 0811, Australia. Email: Selina.Signal@nt.gov.au; Gwendoline.Lowah@nt.gov.au; Jola.Kapojos@sa.gov.au; Asanga.Abeyaratne@nt.gov.au; Madhivanan.Sundaram@nt.gov.au.

Jola Kapojos (J)

Department of Nephrology, Division of Medicine, Royal Darwin Hospital, PO Box 41326, Casuarina, NT 0811, Australia. Email: Selina.Signal@nt.gov.au; Gwendoline.Lowah@nt.gov.au; Jola.Kapojos@sa.gov.au; Asanga.Abeyaratne@nt.gov.au; Madhivanan.Sundaram@nt.gov.au.

Asanga Abeyaratne (A)

Department of Nephrology, Division of Medicine, Royal Darwin Hospital, PO Box 41326, Casuarina, NT 0811, Australia. Email: Selina.Signal@nt.gov.au; Gwendoline.Lowah@nt.gov.au; Jola.Kapojos@sa.gov.au; Asanga.Abeyaratne@nt.gov.au; Madhivanan.Sundaram@nt.gov.au.

Madhivanan Sundaram (M)

Department of Nephrology, Division of Medicine, Royal Darwin Hospital, PO Box 41326, Casuarina, NT 0811, Australia. Email: Selina.Signal@nt.gov.au; Gwendoline.Lowah@nt.gov.au; Jola.Kapojos@sa.gov.au; Asanga.Abeyaratne@nt.gov.au; Madhivanan.Sundaram@nt.gov.au.

Paul Goldrick (P)

Intensive Care Unit, Royal Darwin Hospital, PO Box 40596, Casuarina, NT 0811, Australia. Email: Paul.Goldrick@nt.gov.au; SarahL.Jones@nt.gov.au.

Sarah L Jones (SL)

Intensive Care Unit, Royal Darwin Hospital, PO Box 40596, Casuarina, NT 0811, Australia. Email: Paul.Goldrick@nt.gov.au; SarahL.Jones@nt.gov.au.

Robert McFarlane (R)

Chemical Pathology, Territory Pathology, Department of Health, PO Box 41326, Casuarina, NT 0811, Australia. Email: Robert.McFarlane@nt.gov.au.

Lewis T Campbell (LT)

Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia. Email: william.majoni@nt.gov.au; federica.barzi@nt.gov.au; Tegan.Harris@menzies.edu.au; Lewis.Campbell@nt.gov.au; alan.cass@menzies.edu.au; and Northern Territory Clinical School, Flinders University, Darwin, NT 0811, Australia. Email: Dianne.Stephens@nt.gov.au; and Intensive Care Unit, Royal Darwin Hospital, PO Box 40596, Casuarina, NT 0811, Australia. Email: Paul.Goldrick@nt.gov.au; SarahL.Jones@nt.gov.au.

Dianne Stephens (D)

Northern Territory Clinical School, Flinders University, Darwin, NT 0811, Australia. Email: Dianne.Stephens@nt.gov.au; and Intensive Care Unit, Royal Darwin Hospital, PO Box 40596, Casuarina, NT 0811, Australia. Email: Paul.Goldrick@nt.gov.au; SarahL.Jones@nt.gov.au; and National Critical Care and Trauma Response Centre, Royal Darwin Hospital, Darwin, NT 0810, Australia.

Alan Cass (A)

Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT 0811, Australia. Email: william.majoni@nt.gov.au; federica.barzi@nt.gov.au; Tegan.Harris@menzies.edu.au; Lewis.Campbell@nt.gov.au; alan.cass@menzies.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH